Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11185055 | 0.86 | HSD17B10 (0.48) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL13055383 | 0.85 | LMNA (0.80) | LMNASMN1; SMN2HTTTGM2CA12 | |
| SCHEMBL7657748 | 0.85 | LMNA (0.59) | LMNASMN1; SMN2HTTTGM2POLB | |
| SCHEMBL14260168 | 0.85 | LMNA (0.64) | LMNASMN1; SMN2HTTTGM2POLB | |
| SCHEMBL17244018 | 0.85 | LMNA (0.59) | LMNASMN1; SMN2HTTTGM2POLB | |
| SCHEMBL195242 | 0.85 | TGM2 (0.61) | LMNASMN1; SMN2HTTTGM2POLB | |
| SCHEMBL3826463 | 0.85 | LMNA (0.59) | LMNASMN1; SMN2HTTTGM2POLB | |
| SCHEMBL5019074 | 0.84 | LMNA (0.73) | LMNASMN1; SMN2HTTTGM2CA12 | |
| SCHEMBL28661503 | 0.83 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2HTTTGM2POLB | |
| SCHEMBL21697943 | 0.83 | TPSAB1 (0.46) | LMNASMN1; SMN2HTTTGM2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5998065-A | N-OXYIMIDE ADDITIVE | FUJITSU LIMITED (JP) | 1999-12-07 | — | — | US | claimed |
| US-5225528-A | Controlling premature labor | MERCK & CO., INC. (US) | 1993-07-06 | — | — | US | claimed |
| EP-0444898-A1 | Cyclic hexapeptide oxytocin antagonists | MERCK & CO. INC. (US) | 1991-09-04 | — | — | EP | claimed |
| US-4468512-A | 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | claimed |
| US-4468513-A | 2'-N-Acylated and 2'-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | claimed |
| US-4331804-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1982-05-25 | — | — | US | claimed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12559484-B2 | Route for constructing chiral fragment of fezolinetant, intermediate thereof, and preparation method therefor | SHENZHEN HWAGEN PHARMACEUTICAL CO., LTD. (CN) | 2026-02-24 | — | — | US | disclosed |
| US-20260015345-A1 | ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | SHENZHEN HWAGEN PHARMACEUTICAL CO., LTD. (CN) | 2026-01-15 | — | — | US | disclosed |
| US-12521395-B2 | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2026-01-13 | — | — | US | disclosed |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4055015-B1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-04-02 | — | — | EP | disclosed |
| EP-0356595-A1 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0275101-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0115227-B1 | PEPTIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-03-18 | — | — | EP | disclosed |
| US-4530837-A | Containing tryptophan | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1985-07-23 | — | — | US | disclosed |
| EP-0115227-A1 | Peptide derivatives, process for their preparation and their pharmaceutical use | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1984-08-08 | — | — | EP | disclosed |
| US-4331804-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1982-05-25 | — | — | US | disclosed |
| US-4267180-A | PENICILLINS AND DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015345-A1 | ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | CYP19A1, CYP4F11, CYP11B1 | LMNA 2188/4885SMN1; SMN2 3386/4885HTT 2637/4885 |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | MRPL21, WIZ, CFTR | LMNA 2148/4885SMN1; SMN2 3678/4885HTT 4704/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | LMNA 3037/4885SMN1; SMN2 1576/4885HTT 922/4885 |
| US-12559484-B2 | Route for constructing chiral fragment of fezolinetant, intermediate thereof, and preparation method therefor | PTGIS, TMEM109, CYP11B1 | LMNA 3050/4885SMN1; SMN2 2913/4885HTT 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.